Roche Holding AG / Plexxikon Inc.

BRAF V600E-Mutant Metastatic Melanoma

112K US cases/yr

Disease Overview

Metastatic melanoma is the most aggressive form of skin cancer and historically had a 5-year survival rate of <10% in the distant-stage setting. Roughly 50% of cutaneous melanomas carry an activating BRAF mutation (most commonly V600E), which drives constitutive MAPK pathway signaling and represents the first oncogene-defined targetable subset in melanoma.

Competitive Landscape

When Roche and Plexxikon expanded their original 2006 BRAF collaboration in early 2009 to a full development-and-commercialization pact for PLX4032 (later vemurafenib/Zelboraf), the metastatic melanoma standard of care was dacarbazine — a cytotoxic chemotherapy with response rates of 5-10% and no overall-survival benefit. PLX4032 was the first selective BRAF V600E inhibitor to show meaningful clinical activity, with ~80% partial-or-complete response rates in early Phase 2 V600E-mutant patients. The deal positioned Roche to compete with GlaxoSmithKline's dabrafenib (Tafinlar) and trametinib programs and ipilimumab (Yervoy, BMS) — all of which were advancing in parallel. Vemurafenib was approved in August 2011 alongside the cobas 4800 BRAF V600 companion diagnostic, becoming the first FDA-approved fragment-based-discovery drug and validating the precision-oncology playbook later extended to BRAF+MEK combinations (vemurafenib+cobimetinib/Cotellic) and pan-tumor BRAF use including Erdheim-Chester disease. The 2009 deal was widely seen as one of the most consequential targeted-oncology bets of the era and underwrote Roche's continued leadership in personalized cancer medicine.